お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
971972

トリコモナス症:米国市場の分析、疫学、予測 (2030年)

Trichomoniasis Market Insights, Epidemiology, and Market Forecast-2030 (US)

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 66 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.75円
トリコモナス症:米国市場の分析、疫学、予測 (2030年)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 66 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、米国におけるトリコモナス症の疫学的動向と今後の市場見通しについて分析し、疾患の概要や市場の基本構造、現在の治療法とアンメットニーズ、有病者数の動向見通し、上市済み/治験中の治療薬のプロファイル、米国国内の市場規模 (過去3年間・今後11年間分)、主な市場促進・抑制要因、といった情報を取りまとめてお届けいたします。

目次

第1章 重要な洞察

第2章 トリコモナス症のエグゼクティブサマリー

第3章 トリコモナス症のSWOT分析

第4章 病気の背景と概要

  • イントロダクション
  • 原因
  • 症状
  • 病因
  • トリコモナス症に対する免疫反応
  • 危険因子
  • 臨床所見
  • 診断

第5章 疫学と患者人口

  • 主な調査結果
  • 仮定と理論的根拠:米国
  • 米国
    • トリコモナス症の受診済み有病者数
    • トリコモナス症の有病者数:男女別
    • トリコモナス症の有病者数:年齢別
    • トリコモナス症の有病者数:特異症例別

第6章 治療

第7章 ガイドライン

  • トリコモナス症:CDCによる診断・治療ガイドライン

第8章 アンメットニーズ

第9章 トリコモナス症に貢献している組織

第10章 症例報告

  • トリコモナス症の見逃された診断
  • トリコモナスの家族性・非成功感染への抵抗症例
  • トリッキーなトリコモナス:抵抗の物語

第11章 ペイシェントジャーニー

第12章 上市されている治療薬

第13章 新たな治療薬

  • Secnidazole:Lupin Research Inc
    • 製品説明
    • その他の発達活動
    • 臨床開発
    • 安全性と有効性

第14章 トリコモナス症:市場分析

  • 主な調査結果
  • 市場の将来展望:米国
    • 米国の市場規模

第15章 市場の推進力

第16章 市場の障壁

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Trichomoniasis Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Diagnostic Clues for Vaginal Infections
  • Table 3: Diagnosed Prevalent Cases of Trichomoniasis in the United States (2017-2030)
  • Table 4: Gender-specific Cases of Trichomoniasis in the United States (2017-2030)
  • Table 5: Age-specific Cases of Trichomoniasis in the United States (2017-2030)
  • Table 6: Type-specific Cases of Trichomoniasis by Symptoms in the United States (2017-2030)
  • Table 7: Options for Treating Metronidazole-Resistant Trichomoniasis
  • Table 8: Organizations contributing to Trichomoniasis in the United States
  • Table 9: Secnidazole, Clinical Trial Description, 2020
  • Table 10: United States Market Size of Trichomoniasis in USD Million (2017-2030)
  • Table 11: The US Market Size of Trichomoniasis by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Overview of Diagnostic Assays for Trichomoniasis
  • Figure 3: Diagnosed Prevalent Cases of Trichomoniasis in the United States (2017-2030)
  • Figure 4: Gender-specific Cases of Trichomoniasis in the United States (2017-2030)
  • Figure 5: Age-specific Cases of Trichomoniasis in the United States (2017-2030)
  • Figure 6: Type-specific Cases of Trichomoniasis by Symptoms in the United States (2017-2030)
  • Figure 7: Unmet Needs of Trichomoniasis
  • Figure 8: Market Size of Trichomoniasis in the United States, USD Million (2017-2030)
  • Figure 9: The US Market Size of Trichomoniasis by Therapies in USD Million (2017-2030)
  • Figure 10: Market Drivers of Trichomoniasis
  • Figure 11: Market Drivers of Trichomoniasis
目次
Product Code: DIMI1138

DelveInsight's 'Trichomoniasis Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends of Trichomoniasis in the United States.

The Trichomoniasis market report provides analysis regarding current treatment practices, an emerging drug, like Secnidazole (Lupin Research Inc), potential therapies, market share of the individual therapies, historical, current, and forecasted Trichomoniasis market size from 2017 to 2030 for the United States.

The report also covers current Trichomoniasis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the market's underlying potential.

Geography Covered:

  • The United States

Study Period: 2017-2030

Trichomoniasis - Disease Understanding and Treatment Algorithm

Trichomoniasis Overview

Trichomoniasis (TRIK-uh-muh-NEYE-uh-suhss) or "trich" is a sexually transmitted infection (STI) caused by a parasite; the parasite is spread most often through vaginal, oral, or anal sex. The condition has various public health ramifications and has been associated with vaginitis, cervicitis, urethritis, and pelvic inflammatory disease (PID). Furthermore, it is one of the most common STIs in the United States and affects more women than men. Although it is treated easily with antibiotics, many women do not show any symptoms.

Symptoms can come and go but about 70% of infected people do not have any signs or symptoms. When trichomoniasis does cause symptoms, they can range from mild irritation to severe inflammation. Some people with symptoms get them within 5-28 days after being infected, but others do not develop symptoms until much later. The reason for this is unclear.

Trichomoniasis Treatment

This chapter covers the details of conventional and current medical therapies available in the Trichomoniasis market to treat the condition. It also provides the country-wise Trichomoniasis treatment guidelines across the United States.

DelveInsight's Trichomoniasis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Trichomoniasis treatment algorithms and treatment guidelines in the US.

Trichomoniasis Epidemiology

The Trichomoniasis epidemiology chapters provide insights about historical and current Trichomoniasis patient pool and forecasted trends for the US. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Trichomoniasis epidemiology is segmented by Diagnosed Prevalent Cases of Trichomoniasis, Gender-specific Cases of Trichomoniasis, Cases of Trichomoniasis by Age and Type-specific Cases of Trichomoniasis. The report includes a thorough analysis of all segmentations.

In the US, the cases of Trichomoniasis were 2,570,002 in 2017. Moreover, the Gender-specific cases of Trichomoniasis were highest among females and were reported to be 2,073,893 in the country.

According to DelveInsight's analysis, In the United States, the highest number of Trichomoniasis cases are among 40-49 years of age group followed by 30-39 years.

In the United States, approximately 70% of the Trichomoniasis cases are asymptomatic.

Trichomoniasis Drug Chapters

The drug chapter segment of the Trichomoniasis report encloses the detailed analysis of Trichomoniasis pipeline drug. It also helps understand the Trichomoniasis clinical trial details, expressive pharmacological action, the included drug's agreements, and the latest news and press releases.

Treatment is focused entirely on managing symptoms and supporting the health and well-being of the affected child or adult. The management of Trichomoniasis revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Secnidazole (Lupin Research Inc), etc., for the treatment of Trichomoniasis in the pipeline.

Trichomoniasis Market Outlook

The Trichomoniasis market size is expected to increase at a significant CAGR during the study period (2017-2030). The United States accounts for the Trichomoniasis market size, with USD 30.8 million in 2017.

Trichomoniasis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Trichomoniasis market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Trichomoniasis market uptake by drugs, patient uptake by therapies, and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Trichomoniasis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Trichomoniasis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Trichomoniasis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of Trichomoniasis collaborations, acquisition and merger, licensing, patent details, and other information for Trichomoniasis emerging therapies.

Reimbursement Scenario in Trichomoniasis

Approaching reimbursement, proactively, can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in Trichomoniasis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Trichomoniasis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

  • In the coming years, Trichomoniasis market scenario is expected to alter across the USA due to the launch of novel therapies with new mechanisms of action considering the high unmet medical need.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Trichomoniasis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Trichomoniasis Pipeline Analysis
  • Trichomoniasis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Trichomoniasis Report Key Strengths

  • 11 years Forecast
  • The United States Coverage
  • Trichomoniasis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Trichomoniasis Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Trichomoniasis market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Trichomoniasis total market size as well as market size by therapies across the United States during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across the United States, and which country will have the largest Trichomoniasis market size during the forecast period (2017-2030)?
  • At what CAGR, the Trichomoniasis market is expected to grow in the United States during the forecast period (2017-2030)?
  • What would be the Trichomoniasis market outlook across the United States during the forecast period (2017-2030)?
  • What would be the Trichomoniasis market growth until 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Trichomoniasis?
  • What is the historical Trichomoniasis patient pool in the United States?
  • What would be the forecasted patient pool of Trichomoniasis in the United States?
  • What will be the growth opportunities in the United States with respect to the patient population pertaining to Trichomoniasis?
  • At what CAGR the population is expected to grow in the USA during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the Trichomoniasis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Trichomoniasis in the USA?
  • What is the Trichomoniasis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Trichomoniasis?
  • How many therapies are developed by each company for Trichomoniasis treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for Trichomoniasis treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Trichomoniasis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Trichomoniasis and their status?
  • What are the key designations that have been granted for the emerging therapies for Trichomoniasis?
  • What are the global historical and forecasted market of Trichomoniasis?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Trichomoniasis market
  • To understand the future market competition in the Trichomoniasis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Trichomoniasis in the United States.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • To understand the future market competition in the Trichomoniasis market

What is the forecasted Trichomoniasis market size in 2030?

DelveInsight estimates an increase in Trichomoniasis Market Size during the study period, 2017-2030.

What are the present Trichomoniasis market drivers?

Increasing Prevalence for Trichomoniasis infection and associated complications and increasing demand for Rapid Test Kits and Point of Care

What are the Trichomoniasis market barriers?

Resistance against the standard of care, Epidemiological Data for T. vaginalis Infection and Economic Burden of Trichomoniasis.

How many companies are developing drugs for Trichomoniasis?

Currently, there are many key pharma players engaged in developing the drug for Trichomoniasis in monotherapy.

Which are the leading companies in Trichomoniasis market?

Key Players - Lupin Research Inc.

How is epidemiology segmented for Trichomoniasis?

Prevalent Cases of Trichomoniasis, Trichomoniasis cases by Gender, Trichomoniasis cases by Age and Trichomoniasis cases by types.

Table of Contents

1. Key Insights

2. Executive Summary of Trichomoniasis

3. SWOT Analysis for Trichomoniasis

4. Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Cause
  • 4.3. Symptoms
  • 4.4. Pathogenesis
  • 4.5. Immune response against trichomoniasis
  • 4.6. Risk Factors
  • 4.7. Clinical presentation
  • 4.8. Diagnosis

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Assumptions and Rationale - United States
  • 5.3. The United States
    • 5.3.1. Diagnosed Prevalent Cases of Trichomoniasis in the United States
    • 5.3.2. Gender-specific Cases of Trichomoniasis in the United States
    • 5.3.3. Age-specific Cases of Trichomoniasis in the United States
    • 5.3.4. Type-specific Cases of Trichomoniasis by Symptoms in the United States

6. Treatment

7. Guidelines

  • 7.1. Trichomoniasis: Diagnostic and Treatment Guidelines by CDC

8. Unmet Needs

9. Organizations contributing toward Trichomoniasis

10. Case Reports

  • 10.1. A Missed Diagnosis of Trichomoniasis
  • 10.2. A Resistant Case of Familial Nonsexual Transmission of Trichomonas
  • 10.3. The Tricky Trichomonas: A Tale of Resistance

11. Patient Journey

  • 11.1. Patient Journey: General

12. Marketed Therapies

13. Emerging Therapies

  • 13.1. Secnidazole: Lupin Research Inc
    • 13.1.1. Product Description
    • 13.1.2. Other Development Activities
    • 13.1.3. Clinical Development
    • 13.1.4. Safety and Efficacy

14. Trichomoniasis: Market Analysis

  • 14.1. Key Findings
  • 14.2. Market Outlook: The United States
    • 14.2.1. The United States Market Size

15. Market Drivers

16. Market Barriers

17. Appendix

  • 17.1. Bibliography
  • 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.